Home
 /
Papers
 /
Biochemistry
 /
Zero-shot design of a de novo metalloenzyme
Preprint
Open access
Top 1% · Validated by QED

Zero-shot design of a de novo metalloenzyme

Gina El Nesr, Simon L. Dürr, Irimpan I. Mathews +6 more
April 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.04.23.720277
99
%
QED Score
QED Impressions

By designing a functional bi-zinc phosphatase entirely from scratch—without natural templates or predefined motifs—dEVA overturns the assumption that de novo enzyme design requires evolutionary scaffolding, unlocking programmable biocatalysis at natural-enzyme performance levels.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

The dEVA framework enables zero-shot design of a de novo bi-zinc metalloenzyme without natural templates or evolutionary information, achieving catalytic efficiencies (kcat/KM up to 1500 M⁻¹s⁻¹) and rate enhancements (up to 3×10¹³) comparable to natural phosphatases through multi-objective optimization that balances sequence likelihood with catalytically competent metal coordination geometries.

See full analysis
Main Claim 1 –

dEVA iteratively optimizes proteins across multiple design objectives

Supporting evidence

  • dEVA performance depends on underlying model training data quality
  • Metal3D-Clean and Metal3D-Cat curation improves catalytic design objectives
Main Claim 2 –

dEVA designs de novo metalloproteins with tight zinc coordination

Main Claim 3 –

dEVA zero-shot designs a de novo bi-zinc metalloenzyme

Supporting evidence

  • Mutagenesis and chelation confirm desB activity requires bi-zinc site
  • XAS shows desB bi-zinc geometry with catalytic Zn–Zn distance
Main Claim 4 –

desB reaches natural-like phosphatase catalytic efficiency

Supporting evidence

  • desB binds phosphate and shows competitive inhibition like phosphatases
  • desB promiscuously hydrolyzes phosphomonoesters and phosphodiesters

Abstract

The de novo design of enzymes remains a central challenge, requiring consideration of catalytic mechanism and optimization across biochemical and biophysical criteria. To capture these criteria, we draw on principles from evolutionary biology. Here, we present dEVA (design by EVolutionary Algorithm), a multi-objective design framework for structure-based protein design. We apply dEVA to the zero-shot, de novo design of metalloenzymes by optimizing for the coordination sphere of catalytic metals. We fully characterize one of these designs: a bi-zinc metalloenzyme exhibiting promiscuous hydrolytic activity towards both phosphomonoesters and phosphodiesters. This design achieves a catalytic efficiency (kcat/KM) of up to 1500 M-1s-1 and a rate enhancement ((kcat/KM)/kw) of up to 3 x 1013, comparable to characterized natural phosphatases. dEVA offers a general and modular strategy for the programmable design of protein function without dependence on natural templates, predefined motif, or evolutionary information.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?